Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 84, Issue 4, Pages 1457-1460Publisher
IOS PRESS
DOI: 10.3233/JAD-215275
Keywords
Aducanumab; aduhelm; Alzheimer's disease; amyloid PET; dementia
Categories
Ask authors/readers for more resources
This article discusses the mechanism of action of the FDA-approved anti-Alzheimer drug and the authors' view on the role of amyloid deposits in the progression of the disease.
According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline. The authors of this article are not convinced that amyloid deposits are a hallmark of Alzheimer's disease and are of the opinion that the apparent reduction in amyloid accumulation following aducanumab treatment is likely instead a result of continued and advanced cerebral cell death and, thus, not a sign of improvement but of an even more advanced disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available